CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer | Oncology
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
PDF) CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents
CYP17 inhibitors for prostate cancer therapy. - Abstract - Europe PMC